NORWOOD, Mass., Nov. 11, 2021 /PRNewswire/ -- Corbus
Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the
"Company"), an immunology company, today announced that
Yuval Cohen, Ph.D., Chief Executive
Officer of Corbus, will participate in a fireside chat at the
Jefferies London Healthcare Conference being held virtually and in
person November 16-19, 2021.
An audio webcast of the fireside chat will be available for
viewing on-demand beginning on Thursday,
November 18 at 8:00 AM GMT
(3:00 AM ET) for those registered to
attend the conference and accessible on the Events page of the
Investors section of the Corbus website, www.corbuspharma.com.
The webcast replay will be available and archived for 90 days.
About Corbus
Corbus is committed to connecting innovation to our purpose of
improving lives by developing new medicines that target
inflammation, fibrosis, metabolism and immuno-oncology, by building
upon our underlying expertise in immunology. Corbus' current
pipeline includes small molecules that activate or inhibit the
endocannabinoid system and anti-integrin monoclonal antibodies that
block activation of TGFβ. Corbus is headquartered in Norwood, Massachusetts. For more information
on Corbus, visit corbuspharma.com. Connect with us on Twitter,
LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company's restructuring, trial results, product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of forward-looking
expressions, including, but not limited to, "expect," "anticipate,"
"intend," "plan," "believe," "estimate," "potential," "predict,"
"project," "should," "would" and similar expressions and the
negatives of those terms. These statements relate to future events
or our financial performance and involve known and unknown risks,
uncertainties, and other factors, including the potential impact of
the recent COVID-19 pandemic and the potential impact of sustained
social distancing efforts, on our operations, clinical development
plans and timelines, which may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in
the Company's filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this press release. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
Corbus Pharmaceuticals Contact:
Lindsey Smith, Director, Investor Relations and
Corporate Communications
Phone: +1 (617) 415-7749
Investors: ir@corbuspharma.com
Media: mediainfo@corbuspharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-301421849.html
SOURCE Corbus Pharmaceuticals Holdings, Inc.